Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg tablet for oral suspension
RxNorm 2608540

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2608540 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg tablet for oral suspension.

The following semantic concepts and normalized strings are associated with this clinical entity:

PT
Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg dispersible oral tablet
AUI:12871320
View
SY
Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg tablet for oral suspension
AUI:12871321
View
FN
Product containing precisely abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg/1 each tablet for conventional release oral suspension (clinical drug)
AUI:12756890
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PT

Designated preferred name (PT):
Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg dispersible oral tablet
(Atom ID: 12871320)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg dispersible oral tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2608540
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12871320
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
1197025003
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
SY

Synonym (SY):
Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg tablet for oral suspension
(Atom ID: 12871321)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg tablet for oral suspension
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2608540
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12871321
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1197025003
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
FN

Full form of descriptor (FN):
Product containing precisely abacavir (as abacavir sulfate) 120 mg and lamivudine 60 mg/1 each tablet for conventional release oral suspension (clinical drug)
(Atom ID: 12756890)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing precisely abacavir (as abacavir sulfate) 120 milligram and lamivudine 60 milligram/1 each tablet for conventional release oral suspension (clinical drug)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2608540
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12756890
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
1197025003
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.